Prognostic Value of Biomarkers in RCC

No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

A prospective trial established that 97% of patients were successfully discharged on the same day as receiving robotic partial nephrectomy.

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.